See more : Oncology Pharma Inc. (ONPH) Income Statement Analysis – Financial Results
Complete financial analysis of Polski Bank Komórek Macierzystych S.A. (BKM.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polski Bank Komórek Macierzystych S.A., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Nichicon Corporation (6996.T) Income Statement Analysis – Financial Results
- CDG PETCHEM LIMITED (CDG.BO) Income Statement Analysis – Financial Results
- Ideanomics, Inc. (IDEX) Income Statement Analysis – Financial Results
- Transcontinental Realty Investors, Inc. (TCI) Income Statement Analysis – Financial Results
- MetLife, Inc. (0K0X.L) Income Statement Analysis – Financial Results
Polski Bank Komórek Macierzystych S.A. (BKM.WA)
About Polski Bank Komórek Macierzystych S.A.
Polski Bank Komórek Macierzystych S.A. operates an umbilical cord blood stem cell bank. The company operates through Afterbirth Tissues Banking B2C Services, Afterbirth Tissue Banking B2B Market, and R&D Activities segments. It engages in the processing and storage of human biological material for individual customers and business partners. The company provides diagnostic services; and operates one day hospital and a cell and tissue bank. It also operates diagnostic laboratory and ultrasound scan clinics; operates web portal and provides marketing activities; and conducts research activities. The company offers its services in Serbia, Sweden, Denmark, Ukraine, Germany, and the United States, as well as various Balkan countries and Egypt. Polski Bank Komórek Macierzystych S.A. was founded in 2002 and is based in Warsaw, Poland. Polski Bank Komórek Macierzystych S.A. operates as a subsidiary of AOC Health GmbH.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 211.25M | 187.99M | 161.64M | 148.87M | 128.78M | 104.82M |
| Cost of Revenue | 62.39M | 54.68M | 20.72M | 16.18M | 14.06M | 9.30M |
| Gross Profit | 148.86M | 133.31M | 140.92M | 132.68M | 114.72M | 95.52M |
| Gross Profit Ratio | 70.46% | 70.91% | 87.18% | 89.13% | 89.08% | 91.13% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 35.90M | 24.30M | 47.76M | 38.37M | 35.00M | 31.56M |
| Selling & Marketing | 10.03M | 8.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 45.93M | 32.48M | 47.76M | 38.37M | 35.00M | 31.56M |
| Other Expenses | 97.87M | 84.29M | 48.49M | 51.73M | 49.53M | 48.46M |
| Operating Expenses | 143.80M | 116.77M | 96.24M | 90.10M | 84.53M | 80.02M |
| Cost & Expenses | 206.20M | 171.45M | 116.97M | 106.28M | 98.59M | 89.32M |
| Interest Income | 958.82K | 204.89K | 16.38K | 34.62K | 92.09K | 181.04K |
| Interest Expense | 3.44M | 2.43M | 944.80K | 1.63M | 652.31K | 288.63K |
| Depreciation & Amortization | 17.55M | 12.85M | 6.44M | 5.28M | 4.81M | 4.54M |
| EBITDA | 23.85M | 34.22M | 49.54M | 44.75M | 32.58M | 19.73M |
| EBITDA Ratio | 11.29% | 18.20% | 30.65% | 30.06% | 25.30% | 18.83% |
| Operating Income | 5.05M | 16.54M | 44.67M | 42.58M | 30.19M | 15.50M |
| Operating Income Ratio | 2.39% | 8.80% | 27.64% | 28.60% | 23.45% | 14.79% |
| Total Other Income/Expenses | -2.69M | 1.33M | -2.83M | -4.21M | -1.32M | -179.53K |
| Income Before Tax | 2.36M | 17.87M | 41.84M | 38.37M | 28.88M | 15.32M |
| Income Before Tax Ratio | 1.12% | 9.50% | 25.89% | 25.77% | 22.42% | 14.62% |
| Income Tax Expense | 428.77K | 3.89M | 7.47M | 8.50M | 5.29M | 6.21M |
| Net Income | 2.42M | 15.04M | 34.69M | 29.33M | 21.83M | 8.70M |
| Net Income Ratio | 1.15% | 8.00% | 21.46% | 19.70% | 16.95% | 8.30% |
| EPS | 0.26 | 2.64 | 7.28 | 6.20 | 4.61 | 1.86 |
| EPS Diluted | 0.26 | 2.64 | 7.28 | 6.20 | 4.61 | 1.86 |
| Weighted Avg Shares Out | 9.28M | 5.70M | 4.76M | 4.73M | 4.74M | 4.68M |
| Weighted Avg Shares Out (Dil) | 9.28M | 5.70M | 4.76M | 4.73M | 4.74M | 4.68M |
Source: https://incomestatements.info
Category: Stock Reports